Tesamorelin Compounding Access After FDA Panel Endorses 6 Peptides
FDA panel endorses tesamorelin for 503A compounding, opening off-label obesity and alcohol use disorder research. Cost, safety, and regulatory
Read more →FROM THE LAB JOURNAL
Research & insights
Guides, protocols, and the science behind verified peptides.
Semaglutide Microdosing vs FDA Scrutiny: Off-Label GLP-1 Trends Under Fire
Semaglutide microdosing for off-label uses like cognition and longevity is gaining traction, but FDA warnings and media scrutiny highlight safety and
Read more →Tesamorelin Compounding Guidance Update: FDA Warning on GLP-1 Drugs May Impact GHRH Analog Oversight
FDA's crackdown on compounded semaglutide signals tighter oversight for GHRH analogs like tesamorelin. Compounders face scrutiny over sourcing and
Read more →